Systematic discovery of multicomponent therapeutics
Open accessThe DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Abstract
Multicomponent therapies, originating through deliberate mixing of drugs in a clinical setting, through happenstance, and through rational design, have a successful history in a number of areas of medicine, including cancer, infectious diseases, and CNS disorders. We have developed a high-throughput screening method for identifying effective combinations of therapeutic compounds. We report here that systematic screening of combinations of small molecules reveals unexpected interactions between compounds, presumably due to interactions between the pathways on which they act. Through systematic screening of ≈120,000 different two-component combinations of reference-listed drugs, we identified potential multicomponent therapeutics, including ( i ) fungistatic and analgesic agents that together generate fungicidal activity in drug-resistant Candida albicans , yet do not significantly affect human cells, ( ii ) glucocorticoid and antiplatelet agents that together suppress the production of tumor necrosis factor-α in human primary peripheral blood mononu-clear cells, and ( iii ) antipsychotic and antiprotozoal agents that do not exhibit significant antitumor activity alone, yet together prevent the growth of tumors in mice. Systematic combination screening may ultimately be useful for exploring the connectivity of biological pathways and, when performed with reference-listed drugs, may result in the discovery of new combination drug regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“combinations of chemical agents (or manipulations such as those of transcription factors that affect multiple steps in a pathway [1906] or modulation of multiple gene products [2311], or both [2312,2313]) will be far more efficacious, for instance in modulating iron-catalysed oxidative stress and its sequelae, than will be the use of 'magic bullet' single agents.”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1704]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Systems biology: a brief overview
Kitano, H. (2002) · Science · doi:10.1126/science.1069492 · Cited by 4,265
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
The KEGG databases at GenomeNet
Kanehisa, M. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.42 · Cited by 1,504
Berenbaum, M. C. (1989) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00026-2 · Cited by 1,414
The Sanford guide to antimicrobial therapy
Gilbert, D. N., Moellering, R. C., Eliopoulos, G. M., Chambers, H. F., & Saag, M. S. (1996) · Cited by 1,361
Lieber, M., Todaro, G., Smith, B., Szakal, A., & Nelson‐Rees, W. (1976) · International Journal of Cancer · doi:10.1002/ijc.2910170110 · Cited by 1,283
(1953) · PubMed · Cited by 942
Resistance of Candida species to fluconazole
Rex, J. H., Rinaldi, M. G., & Pfaller, M. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.1 · Cited by 877
Analysis of combined drug effects: a new look at a very old problem
Chou, T.-C., & Talalay, P. (1983) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(83)90490-x · Cited by 619
Mechanism-Based Target Identification and Drug Discovery in Cancer Research
Gibbs, J. B. (2000) · Science · doi:10.1126/science.287.5460.1969 · Cited by 606
Smart drugs: Tyrosine kinase inhibitors in cancer therapy
Shawver, L. K., Slamon, D., & Ullrich, A. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00039-9 · Cited by 522
Haskó, G., Kuhel, D. G., Chen, J.-F., Schwarzschild, M. A., Deitch, E. A., Mabley, J. G., Marton, A., & Szabó, C. (2000) · The FASEB Journal · doi:10.1096/fj.99-0508com · Cited by 512
Criteria for Analyzing Interactions between Biologically Active Agents
(1981) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60912-4 · Cited by 454
Kalgutkar, A. S., Crews, B. C., Rowlinson, S. W., Marnett, A. B., Kozak, K. R., Remmel, R. P., & Marnett, L. J. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.2.925 · Cited by 252
STI571 (Gleevec™) as a paradigm for cancer therapy
Druker, B. J. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02305-5 · Cited by 245
Die quantitativen Probleme der Pharmakologie
Loewe, S. (1928) · Ergebnisse der Physiologie · doi:10.1007/bf02322290 · Cited by 229
Shaheen, R. M., Tseng, W. W., Davis, D. W., Liu, W., Reinmuth, N., Vellagas, R., Wieczorek, A. A., Ogura, Y., McConkey, D. J., Drazan, K. E., et al. (2001) · PubMed · Cited by 181
Brent, R. (2000) · Cell · doi:10.1016/s0092-8674(00)81693-1 · Cited by 148
Glucocorticoid modulation of human monocyte/macrophage function: Control of TNF-α secretion
Joyce, D. A., Steer, J. H., & Abraham, L. J. (1997) · Inflammation Research · doi:10.1007/s000110050222 · Cited by 128
Inhibition of human monocyte TNF production by adenosine receptor agonists
Vraux, V. L., Chen, Y. L., Masson, I., Sousa, M. D., Giroud, J., Florentin, I., & Chauvelot‐Moachon, L. (1993) · Life Sciences · doi:10.1016/0024-3205(93)90632-d · Cited by 112
Effects of psychotropic drugs on cell proliferation and differentiation
Nordenberg, J., Fenig, E., Landau, M., Weizman, R., & Weizman, A. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00156-2 · Cited by 110
Structure and DNA binding activity of analogs of 1,5-bis(4-amidinophenoxy)pentane (pentamidine)
Cory, M., Tidwell, R. R., & Fairley, T. A. (1992) · Journal of Medicinal Chemistry · doi:10.1021/jm00081a003 · Cited by 105
Marshak, D. R., Lukas, T. J., & Watterson, D. M. (1985) · Biochemistry · doi:10.1021/bi00322a020 · Cited by 96
Endogenous Adenosine Curtails Lipopolysaccharide‐Stimulated Tumour Necrosis Factor Synthesis
Eigler, A., Greten, T. F., Sinha, B. N. M., Haslberger, C., Sullivan, G. W., & Endres, S. (1997) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.1997.d01-377.x · Cited by 94
The cell cycle and development: redundant roles of cell cycle regulators
Zhang, P. (1999) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(99)00032-0 · Cited by 84
Chemical ligands, genomics and drug discovery
Lenz, G. R., Nash, H. M., & Jindal, S. (2000) · Drug Discovery Today · doi:10.1016/s1359-6446(00)01468-9 · Cited by 84
Basselin, M., Badet‐Denisot, M., Lawrence, F., & Robert-Géro, M. (1997) · Experimental Parasitology · doi:10.1006/expr.1996.4131 · Cited by 63
Targets of glucocorticoid action on TNF-α release by macrophages
Joyce, D. A., Gimblett, G., & Steer, J. H. (2001) · Inflammation Research · doi:10.1007/pl00012387 · Cited by 62
Chlorpromazine-induced damage on nucleic acids: a combined cytogenetic and biochemical study
Lialiaris, T. S., Pantazaki, Α. A., Sivridis, E., & Mourelatos, D. (1992) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/0027-5107(92)90044-3 · Cited by 49
Lazo, J. S., Chen, D. L., Gallicchio, V. S., & Hait, W. N. (1986) · PubMed · Cited by 40
Mokbel, K., & Hassanally, D. A. (2001) · Current Medical Research and Opinion · doi:10.1185/0300799039117027 · Cited by 37
Chlorpromazine: a potential anticancer agent?
Darkin, S. J., McQuillan, J., & Ralph, R. K. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80352-6 · Cited by 32
Wershil, B. K., Furuta, G. T., Lavigne, J. A., Choudhury, A. R., Wang, Z. S., & Galli, S. J. (2009) · International Archives of Allergy and Immunology · doi:10.1159/000237015 · Cited by 31
Phenazopyridine in Urinary Tract Infections
Zelenitsky, S. A., & Zhanel, G. G. (1996) · Annals of Pharmacotherapy · doi:10.1177/106002809603000727 · Cited by 28
Kitamura, Y., Arima, T., Imaizumi, R., Sato, T., & Nomura, Y. (1995) · European Journal of Pharmacology Molecular Pharmacology · doi:10.1016/0922-4106(95)90107-8 · Cited by 26
Hait, W. N., Lazo, J. S., Chen, D.-L., Gallichio, V. S., & Filderman, A. E. (1988) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/80.4.246 · Cited by 22
Characteristics of a serially propagated human diploid cell designated MRC-9
Jacobs, J. P., Garrett, A. J., & Merton, R. E. (1979) · Journal of Biological Standardization · doi:10.1016/s0092-1157(79)80043-8 · Cited by 16
Paclitaxel activity, dose, and schedule: data from phase III trials in metastatic breast cancer.
Leo, A. D., & Piccart, M. J. (1999) · PubMed · Cited by 13
The current status of adjuvant chemotherapy for resected non-small cell lung cancer.
Socinski, M. A. (1999) · PubMed · Cited by 10
Pérez, J. M., Requena, J. M., Craciunescu, D. G., Doadrio, A. L., & Alonso, C. (1993) · Chemico-Biological Interactions · doi:10.1016/0009-2797(93)03199-5 · Cited by 7
In vivo toxicity of phenothiazines to cells of a transplantable tumor
Lehnert, S. (1986) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00293990 · Cited by 7
Interferon response to dipyridamole in lupus erythematosus patients
Konstantinov, K. N., Galabov, A. S., & Mastikova, M. (1989) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1989.tb01400.x · Cited by 3
Research works printed but not linked: 10
- Shaheen, R. M., Tseng, W. W., Davis, D. W., Liu, W., Reinmuth, N., Vellagas, R., Wieczorek, A. A., Ogura, Y., McConkey, D. J., Drazan, K. E., et al. (2001) Cancer Res. 61, 1464-1468.11245452
- Berenbaum, M. C. (1989) Pharmacol. Rev. 2, 93-141.
- Loewe, S. (1953) Arzneim.-Forsch. 3, 285-290.13081480
- DeVita V. T. Jr. (1997) in Principles of Cancer Management: Chemotherapy eds. DeVita V. T. Jr. Hellman S. & Rosenberg S. A. (Lippincott Philadelphia) pp. 333-347.
- Di Leo, A. & Piccart, M. J. (1999) Semin. Oncol. 26, 27-32.
- Fraser, T. R. (1871) Proc. Roy. Soc. Edinburgh 7, 506-511.
- Konstantinov, K., Galabov, A. & Mastikova, M. (1989) Br. J. Dermatol. 121, 59-63.2757956
- Hardman J. G. & Limbird L. E. (2001) Goodman and Gilman's The Pharmacological Basis of Therapeutics (McGraw–Hill New York) 10th Ed.
- Lazo, J. S., Chen, D. L., Gallicchio, V. S. & Hait, W. N. (1986) Cancer Res. 46, 2236-2240.2421873
- Lowe, P. R., Sansom, C. E., Schwalbe, C. H. & Stevens, M. F. G. (1989) J. Chem. Soc. Chem. Commun. 16, 1164-1165.
Cited by
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
“Likewise, systematic combination screening of approximately 1,000 US Food and Drug Administration (FDA)-approved drugs required the use of high-throughput screening methods to assay the massive data matrix required for the factorial isobolgram analysis of each combination through the full dose rang”
MethodAntibacterial drug discovery in the resistance era
Brown, E. D., & Wright, G. D. (2016) · Nature · doi:10.1038/nature17042 · Cited by 2,247
The Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1691 · Cited by 1,379
“Recent studies suggest that it is possible to screen pairwise combinations of drugs against ISOGENIC cell lines to uncover novel drug–gene and drug–drug interaction”
BackgroundAnalysis of drug combinations: current methodological landscape
Foucquier, J., & Guedj, M. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.149 · Cited by 1,115
“2013) but do not mention how methods are implemented (Raffa et al. 2000; Borisy et al. 2003; Leh ar et al. 2007, 2009; Cokol et al. 2011).”
MethodMulti-target therapeutics: when the whole is greater than the sum of the parts
Zimmermann, G. R., Lehár, J., & Keith, C. T. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.11.008 · Cited by 1,105
Self-citation
Metadata
- Authors
- Borisy, A. A., Elliott, P. J., Hurst, N. W., Lee, M. S., Lehár, J., Price, E. R., Serbedzija, G., Zimmermann, G. R., Foley, M. A., Stockwell, B. R., & Keith, C. T.
- Affiliations
- CombinatoRx Incorporated, 650 Albany Street, Boston, MA 02118
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2003-06-10
- Volume
- 100
- Issue
- 13
- Pages
- 7977-7982
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC164698
- OpenAlex
- W2115147179
- Cited by
- 620
- References
- 44
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 14 · 2023: 38 · 2022: 21 · 2021: 24 · 2020: 29 · 2019: 28 · 2018: 27 · 2017: 26 · 2016: 47 · 2015: 52 · 2014: 36 · 2013: 31 · 2012: 35
- FWCI
- 17.60
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Columbia Academic Commons (Columbia University)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Pharmacology (medical) › Historical Medical Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Science, Research, and Medicine
- Keywords
- drug combination screening, high-throughput screening, drug interactions, pathway interactions, fungicidal activity, glucocorticoids, antiplatelet agents, TNF-α, antipsychotic drugs, antiprotozoal agents, anticancer activity, combination therapy
- MeSH terms
- Animals, Antifungal Agents, Automation, Candida albicans, Cell Division, Colony-Forming Units Assay, Dose-Response Relationship, Drug, Drug Resistance, Microbial, Drug Evaluation, Preclinical, Drug Screening Assays, Antitumor, Enzyme-Linked Immunosorbent Assay, Humans, Interferon-gamma, Neoplasm Transplantation, Neoplasms, RNA, Tumor Cells, Cultured, Tumor Necrosis Factor-alpha, Drug Design, Fluconazole, Cytokines, DNA, Complementary, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.